A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)

被引：0
|
作者：
Beeram, M.
Krop, I.
Modi, S.
Tolcher, A.
Rabbee, N.
Girish, S.
Tibbitts, J.
Holden, S.
Lutzker, S.
Burris, H.
机构：
[1] Inst Drug Dev, San Antonio, TX USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Sarah Cannon Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab-MCC-DM1 (TMAB-MCC-DM1), a first-in-class her2 antibody-drug conjugate (ADC) - A phase I study in patients (PTS) with Her2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I. E.
    Modi, S.
    Tolcher, A. W.
    Tibbitts, J.
    Rabbees, N.
    Girish, S.
    Lutzker, S. G.
    Holden, S. N.
    Burris, H. A.
    ANNALS OF ONCOLOGY, 2007, 18 : 21 - 21
  • [2] A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+breast cancer (BC)
    Beeram, M.
    Burris, H. A., III
    Modi, S.
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Krop, I. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 219 - 219
  • [4] A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): Final results
    Vogel, C. L.
    Burris, H. A.
    Limentani, S.
    Borson, R.
    O'Shaughnessy, J.
    Vukelja, S.
    Agresta, S.
    Klencke, B.
    Birkner, M.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Vukelja, S.
    Rugo, H.
    Vogel, C.
    Borson, R.
    Tan-Chiu, E.
    Birkner, M.
    Holden, S. N.
    Klencke, B.
    O'Shaughnessy, J.
    Burris, H. A.
    CANCER RESEARCH, 2009, 69 (02) : 71S - 71S
  • [6] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [7] A PHASE 2 STUDY OF THE HER2 ANTIBODY-DRUG CONJUGATE TRASTUZUMAB-DM1 (T-DM1) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH TRASTUZUMAB, LAPATINIB, AND CHEMOTHERAPY
    Krop, I.
    LoRusso, P.
    Miller, K. D.
    Modi, S.
    Yardley, D.
    Rodriguez, G.
    Lu, M.
    Burington, B.
    Agresta, S.
    Rugo, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 97 - 97
  • [8] AN INTEGRATED POPULATION PHARMACOKINETIC MODEL FOR A FIRST-IN-CLASS HER2 TARGETED ANTIBODYDRUG CONJUGATE TRASTUZUMAB-DM1 (T-DM1): SIMULTANEOUS MODELING OF T-DM1 AND TOTAL TRASTUZUMAB PHARMACOKINETICS IN HEAVILY PRETREATED HER2+METASTATIC BREAST CANCER PATIENTS.
    Lu, D.
    Gupta, M.
    Wang, B.
    Joshi, A.
    Theil, F.
    Krop, I.
    Burris, H.
    Yi, J.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S54 - S54
  • [9] Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+metastatic breast cancer (MBC): phase I and phase II trial results
    Burris, H., III
    Vukelja, S.
    Krop, I.
    Modi, S.
    Klencke, B.
    Girish, S.
    Sliwkowski, M. X.
    Dresser, M.
    Phillips, G. L.
    Rugo, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 266 - 267
  • [10] Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
    Lambert, John M.
    Chari, Ravi V. J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (16) : 6949 - 6964
12345